Replies to post #133972 on Biotech Values

[DewDiligence]

This is big enough to move the needle even for PFE. In due course, I expect wide uptake in older adults.

[DewDiligence]

Prevnar 13 for adults 50+ will be discussed at the CDC’s ACIP meeting in February:

http://www.cdc.gov/vaccines/recs/acip/downloads/agenda-feb12.pdf

(23-Feb-2012 8:30am): 13-valent Pneumococcal Conjugate Vaccine (PCV13)

• Introduction – Dr. Nancy Bennett (ACIP, WG Chair)

• Pneumococcal conjugate vaccine for adults 50 years of age or older: background and review of data – Ms. Tamara Pilishvili (CDC/NCIRD)

• Pneumococcal conjugate vaccine for adults with immunocompromising conditions: background and review of data – Dr. Kathleen Dooling (CDC/NCIRD)

• Considerations for adult vaccination: GRADE – Ms. Tamara Pilishvili (CDC/NCIRD)

Although no formal vote on the use of Prevnar 13 in adults age 50+ is on the agenda for this meeting, the discussion by ACIP could have a significant effect on the commercial uptake of the product. PFE’s US product launch is scheduled for Mar 2012.